Glenmark Pharmaceuticals Inc. , USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S.FDA) for riamcinolone Acetonide Ointment USP, 0.1 percent, the generic version of Kenalog Ointment, 0.1 percent, of Mylan Pharmaceuticals Inc.

According to IMS Health sales data for the 12 month period ending June 2017, the Kenalog Ointment, 0.1% market1 achieved annual sales of approximately USD 26.3 million.Glenmark's current portfolio consists of 122 products authorized for distribution in the U.S.marketplace and 64 ANDA's pending approval with the U.S.FDA.In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.